View Post

MD Anderson Begins Lymphoma Trial for Oncoceutics’ ONC201

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced that patient enrollment for a clinical trial of the company’s lead compound ONC201 in non-Hodgkin’s lymphoma has started at The University of Texas MD Anderson Cancer Center (MDACC). The trial, identified as NCT02420795 on, is entitled “Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma.” The Phase I/II trial will investigate the use …

CHMP recommends EU approval of Roche’s Subcutaneous Herceptin for HER2 positive breast cancer

In In The News by Barbara Jacoby

(Menafn – M2 PRESSWIRE via COMTEX) New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients’ time Herceptin is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (six:RO)(six:ROG)(otcqx:RHHBY) is pleased to announce that the …